India Proposes Stricter Drug Licensing Regulations for Non-Compliant Firms
Centre may bar cancelled drug licence holders from seeking fresh approvals
Business Standard
Image: Business Standard
The Indian government is considering a proposal to prevent companies and individuals with previously cancelled drug licenses from reapplying. This move aims to enhance regulatory measures and ensure compliance with good manufacturing practice (GMP) standards in the pharmaceutical industry.
- 01The Centre is considering barring firms with cancelled drug licenses from future applications.
- 02The proposal aims to strengthen pharmaceutical regulations in India.
- 03Public disclosure of inspection findings is also being proposed.
- 04This initiative targets non-compliance with good manufacturing practices (GMP).
- 05The move reflects a broader effort to improve drug safety and quality.
Advertisement
In-Article Ad
In an effort to enhance pharmaceutical regulation, the Indian government is contemplating a proposal that would prevent companies and individuals whose drug licenses have been cancelled for non-compliance with good manufacturing practice (GMP) standards from seeking new licenses. This initiative aims to tighten the regulatory framework governing the pharmaceutical industry, ensuring that only compliant entities can operate. Additionally, the proposal includes the public disclosure of inspection findings to promote transparency and accountability within the sector. These measures are part of a broader strategy to improve drug safety and quality in India.
Advertisement
In-Article Ad
This proposal could significantly affect pharmaceutical companies in India, particularly those that have faced license cancellations. It may lead to stricter compliance requirements and enhance the overall quality of drugs available to consumers.
Advertisement
In-Article Ad
Reader Poll
Do you support stricter regulations on drug licensing in India?
Connecting to poll...
Read the original article
Visit the source for the complete story.